12:06 PM EDT, 06/02/2025 (MT Newswires) -- ImmunityBio ( IBRX ) shares were up nearly 6% after the company said the US Food and Drug Administration authorized expanded access to its Cancer BioShield platform and Anktiva immunotherapy to treat lymphopenia, a severe immune deficiency, in patients with solid tumors.

The FDA's decision allows Anktiva to be used in patients whose solid tumors have progressed after first-line chemotherapy, radiotherapy, or immunotherapy and who exhibit low absolute lymphocyte counts, regardless of tumor type.

Anktiva was previously approved in April 2024 in combination with Bacillus Calmette-Guerin to treat certain forms of non-muscle-invasive bladder cancer.

Price: 2.82, Change: +0.16, Percent Change: +5.83